These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 23887645

  • 1. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
    Pezuk JA, Brassesco MS, Morales AG, de Oliveira JC, de Paula Queiroz RG, Machado HR, Carlotti CG, Neder L, Scrideli CA, Tone LG.
    Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.
    Pezuk JA, Brassesco MS, Morales AG, de Oliveira JC, de Oliveira HF, Scrideli CA, Tone LG.
    Cancer Biother Radiopharm; 2013 Sep; 28(7):516-22. PubMed ID: 23713868
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H, Tao Z, Feng M, Li X, Deng Z, Zhao G, Yin H, Pan T, Chen G, Feng Z, Li Y, Zhou Y.
    Biochem Biophys Res Commun; 2020 Dec 10; 533(3):368-375. PubMed ID: 32962858
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB, Woo SU, Yim H.
    J Cell Physiol; 2015 Dec 10; 230(12):3057-67. PubMed ID: 25975351
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
    Chou YS, Yen CC, Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH, Liu CL.
    Int J Oncol; 2016 Mar 10; 48(3):1187-94. PubMed ID: 26794530
    [Abstract] [Full Text] [Related]

  • 11. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A, Hugle M, Fulda S.
    Cancer Lett; 2015 Aug 28; 365(1):37-46. PubMed ID: 25917079
    [Abstract] [Full Text] [Related]

  • 12. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.
    Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK.
    Cancer Res; 2015 Dec 15; 75(24):5355-66. PubMed ID: 26573800
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.
    Cell Cycle; 2011 Apr 15; 10(8):1303-11. PubMed ID: 21436619
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M, Bakar-Ates F.
    Chem Biol Interact; 2020 Dec 01; 332():109288. PubMed ID: 33075310
    [Abstract] [Full Text] [Related]

  • 18. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F, Fink AL, Kiyokawa J, Miller JJ, Koerner MVA, Cahill DP, Wakimoto H.
    Mol Cancer Ther; 2018 Dec 01; 17(12):2551-2563. PubMed ID: 30217967
    [Abstract] [Full Text] [Related]

  • 19. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.
    Leukemia; 2009 Sep 01; 23(9):1564-76. PubMed ID: 19421227
    [Abstract] [Full Text] [Related]

  • 20. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA, Raab M, Becker S, Strebhardt K.
    Biochim Biophys Acta Rev Cancer; 2021 Jan 01; 1875(1):188467. PubMed ID: 33171265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.